期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; 39 (1)
Purpose: To determine the appropriate dose frequency for the second-generation fluoroquinolones (2FQs), ciprofloxacin 0.3% and ofloxacin 0.3%, in the ......
期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; 39 (4)
Purpose: To evaluate the hypothesis that 3 novel compounds, OXT-328, Q-922, and CL-717 show efficacy in the treatment of oxygen-induced retinopathy (O......
期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; 39 (9)
Currently, corneal blindness is affecting >10 million individuals worldwide, and there is a significant unmet medical need because only 1.5% of tra......
期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; ()
Purpose: The purpose of this study was to compare the efficacy, and ocular pharmacokinetics of a new 0.04% w/v bis in die means twice a day (BID) opht......
期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; 39 (1)
Purpose: Age-related macular degeneration (AMD) is a leading cause of blindness in developed countries with little in the way of treatment that preven......
期刊： JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2023; 39 (1)
Purpose: To compare the efficacy and ocular tolerability of a 0.08% nanoemulsion cyclosporine A (CsA) (TJO-087) once daily versus a conventional 0.05%......
